Joseph J Park, Alec Chu, Jinju Li, Alicia Ali, Rana R McKay, Clara Hwang, Matthew K Labriola, Albert Jang, Deepak Kilari, George Mo, Deepak Ravindranathan, Laura S Graham, Alexandra Sokolova, Abhishek Tripathi, Amanda Pilling, Tanya Jindal, Aditya Ravindra, Frank C Cackowski, Patrick L Sweeney, Bicky Thapa, Taylor S Amery, Elisabeth I Heath, Rohan Garje, Yousef Zakharia, Vadim S Koshkin, Mehmet A Bilen, Michael T Schweizer, Pedro C Barata, Tanya B Dorff, Marcin Cieslik, Ajjai S Alva, Andrew J Armstrong
PURPOSE: There are limited data available on the real-world patterns of molecular testing in men with advanced prostate cancer. We thus sought to evaluate next-generation sequencing (NGS) testing in the United States, focused on single versus serial NGS testing, the different disease states of testing (hormone-sensitive v castration-resistant, metastatic vs nonmetastatic), tissue versus plasma circulating tumor DNA (ctDNA) assays, and how often actionable data were found on each NGS test...
April 2024: JCO Precision Oncology